SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
07 Marzo 2024 - 6:49AM
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty
clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders and rare diseases of the central
nervous system, announced today that the process of granting and
validation for its core-technology patent has been completed in
certain European countries. This patent covers combinations of
cannabinoids and n-acylethanolamines (the “Patent”). The Patent
aligns seamlessly with the Company's proprietary technology
designed to enhance the safety of cannabinoids by using low dosages
of active components while maintaining their therapeutic benefits.
The Patent was granted and validated in Austria,
Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands,
Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein and the
United Kingdom.
This grant adds to the patent portfolio of the
Company, thereby supporting the innovation of SciSparc’s
technologies.
The invention relates to compositions and
methods for potentiating therapeutic effects and/or reducing the
side-effects of selected cannabinoids initially discovered in the
cannabis plant. The Patent approval was granted on account of the
unique composition of cannabinoids and n-acylethanolamines and the
methods for their use in preventing and treating a variety of
cannabinoid-treated conditions.
About SciSparc Ltd. (Nasdaq:
SPRC):
SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. SciSparc’s focus is on creating and
enhancing a portfolio of technologies and assets based on
cannabinoid pharmaceuticals. With this focus, the Company is
currently engaged in the following drug development programs based
on THC and/or non-psychoactive CBD: SCI-110 for the treatment of
Tourette Syndrome, for the treatment of Alzheimer's disease and
agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of ASD and status epilepticus. The Company also owns a
controlling interest in a subsidiary whose business focuses on the
sale of hemp seeds oil-based products on the Amazon.com
Marketplace.
Investor Contact:IR@scisparc.comTel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
SciSparc (NASDAQ:SPRC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024